Houman Ashrafian
Chief Tech/Sci/R&D Officer chez SANOFI
Profil
Houman Ashrafian is the founder of Heart Metabolics Ltd.
(founded in 2014), HMBL Ltd.
(founded in 2004), and TRex Bio Ltd.
(founded in 2018).
Dr. Ashrafian was also the founder of Dualitas Ltd., Catamaran Bio, Inc., Weatherden Ltd., Sitryx Therapeutics Ltd., Alchemab Therapeutics Ltd., Mestag Therapeutics Ltd., Enara Bio Ltd.
Dr. Ashrafian's current job(s) included being a Director at Ervaxx Ltd.
(since 2016), Zarodex Therapeutics Ltd.
(since 2017), Cellinta Ltd.
(since 2020), Cybele Therapeutics Ltd.
(since 2019), and a Scientific Advisor at SV Health Investors LLP (since 2016).
Dr. Ashrafian is also the Managing Partner at SV Health Managers LLP (since 2016).
Additionally, Dr. Ashrafian will be the Executive VP, Head-Research & Development at Sanofi starting in 2023.
Dr. Ashrafian's former job(s) include being the Chairman of Therini Bio, Inc., a Director at Imbria Pharmaceuticals, Inc., and a Director at Prilenia Therapeutics BV.
Dr. Ashrafian's education includes an undergraduate degree from the University of Oxford in 1999, a doctorate degree from the University of Oxford in 2009, and undergraduate and graduate degrees from the University of Cambridge.
Postes actifs de Houman Ashrafian
| Sociétés | Poste | Début |
|---|---|---|
| SANOFI | Chief Tech/Sci/R&D Officer | 11/09/2023 |
Weatherden Ltd.
 Weatherden Ltd. BiotechnologyHealth Technology Weatherden Ltd. is a pioneering clinical development consulting group based in London, UK. The British company specializes in scientific strategy, translational medicine, clinical development, diligence preparation, and support for M & A. Weatherden focuses on de-risking programs early and optimizing clinical, regulatory, and commercial pathways to bring life-changing medicines to patients. With over 750 years of combined industry experience, they are dedicated to improving the chances for breakthrough therapies to address unmet clinical needs. The private company, founded by Duncan McHale and Houman Ashrafian, provides trusted advice to biopharma, funds, startups, spin-outs, and nonprofits. Emma Tinsley has been the CEO of the company since 2017. | Founder | - |
SV Health Managers LLP
 SV Health Managers LLP Investment ManagersFinance SV Health Managers LLP (SVHM) is the investment management subsidiary of SV Life Sciences Advisers LLP in the UK. Established in 2005, the firm was formerly known as SV Life Sciences Managers LLP and changed their name to SV Health Managers LLP in 2017. Based in London, the firm manages the International Biotechnology Trust plc (LSE: IBT), an investment trust vehicle listed on the London Stock Exchange into which corporate and private investors may invest. | Portfolio Manager-Equities | 01/01/2016 |
Zarodex Therapeutics Ltd.
 Zarodex Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Zarodex Therapeutics Ltd. engages in the research and experimental development on biotechnology. The company was founded on July 26, 2017 and is headquartered in London, the United Kingdom. | Director/Board Member | 26/07/2017 |
Cellinta Ltd.
 Cellinta Ltd. Investment ManagersFinance Cellinta Ltd. operates as a biotechnology firm. The company was founded on August 16, 2019 and is headquartered in Reading, the United Kingdom. | Director/Board Member | 10/03/2020 |
Cybele Therapeutics Ltd.
 Cybele Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Cybele Therapeutics Ltd. engages in research and experimental development on biotechnology. The company was founded on August 23, 2019 and is headquartered in Reading, the United Kingdom. | Director/Board Member | 11/12/2019 |
Ervaxx Ltd.
 Ervaxx Ltd. Pharmaceuticals: MajorHealth Technology Ervaxx Ltd. is a British company that pioneers the use of dark antigens to deliver targeted immunotherapies for treating and preventing cancer. The company was founded in 2016 by George Kassiotis, Drew M. Pardoll and is based in London, UK. The company's powerful, proprietary edapt platform has been developed to discover and validate dark antigens providing an in-depth assessment of candidate antigens on primary tumor cells along with their immunogenic potential. Ervaxx is advancing a pipeline of T cell receptor-based therapies, off-the-shelf cancer vaccines, and other immunotherapies leveraging these insights into the role of dark antigens in cancer. | Director/Board Member | 08/11/2016 |
SV Health Investors LLP
 SV Health Investors LLP Investment ManagersFinance SV Health Investors LLP (SV Health Investors) is an Independent Venture Capital firm founded in 1994 by Peter McPartland. The firm is headquartered in London. | Private Equity Investor | 01/01/2016 |
Anciens postes connus de Houman Ashrafian
| Sociétés | Poste | Fin |
|---|---|---|
| HMBL Ltd. | Founder | 03/06/2017 |
| ░░░░░░░░░ ░░░░ ░░░░ | ░░░░░░░ | - |
| ░░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░ | - |
| ░░░░ ░░░ ░░░░ | ░░░░░░░ | - |
| ░░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░ | - |
Formation de Houman Ashrafian
| University of Oxford | Undergraduate Degree |
| University of Cambridge | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| SANOFI | Commercial Services |
| Entreprise privées | 19 |
|---|---|
SV Health Investors LLP
SV Health Investors LLP Investment ManagersFinance SV Health Investors LLP (SV Health Investors) is an Independent Venture Capital firm founded in 1994 by Peter McPartland. The firm is headquartered in London. | Finance |
SV Health Managers LLP
SV Health Managers LLP Investment ManagersFinance SV Health Managers LLP (SVHM) is the investment management subsidiary of SV Life Sciences Advisers LLP in the UK. Established in 2005, the firm was formerly known as SV Life Sciences Managers LLP and changed their name to SV Health Managers LLP in 2017. Based in London, the firm manages the International Biotechnology Trust plc (LSE: IBT), an investment trust vehicle listed on the London Stock Exchange into which corporate and private investors may invest. | Finance |
Heart Metabolics Ltd.
 Heart Metabolics Ltd. BiotechnologyHealth Technology Heart Metabolics Ltd. operates as a biopharmaceutical company that engages in developing new treatments for orphan disease including cardio-metabolic diseases. The firm provides drugs to treat heart failure for hypertrophic cardiomyopathy patients. The company was founded by Michael Paul Frenneaux and Houshman Ashrafian in 2004 and is headquartered in Dublin, Ireland. | Health Technology |
| HMBL Ltd. | Commercial Services |
Dualitas Ltd.
 Dualitas Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Envisics LLC, Dualitas Ltd. is a British company that engages in developing technologies to deliver holographic and augmented reality products and services. The private company is based in London, UK. The company was founded in 2016 by Houman Ashrafian. | Commercial Services |
Weatherden Ltd.
Weatherden Ltd. BiotechnologyHealth Technology Weatherden Ltd. is a pioneering clinical development consulting group based in London, UK. The British company specializes in scientific strategy, translational medicine, clinical development, diligence preparation, and support for M & A. Weatherden focuses on de-risking programs early and optimizing clinical, regulatory, and commercial pathways to bring life-changing medicines to patients. With over 750 years of combined industry experience, they are dedicated to improving the chances for breakthrough therapies to address unmet clinical needs. The private company, founded by Duncan McHale and Houman Ashrafian, provides trusted advice to biopharma, funds, startups, spin-outs, and nonprofits. Emma Tinsley has been the CEO of the company since 2017. | Health Technology |
Imbria Pharmaceuticals, Inc.
 Imbria Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Imbria Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company developing novel therapies that restore cellular energy deficits. It focuses on restoring or improving the cell?s ability to produce energy where energy imbalances are at the root of disease, including cardiovascular diseases and inborn errors of metabolism. The company was founded by Andrew Levin and David-Alexandre C. Gros in 2018 and is headquartered in Boston, MA. | Health Technology |
Sitryx Therapeutics Ltd.
 Sitryx Therapeutics Ltd. Medical SpecialtiesHealth Technology Sitryx Therapeutics Ltd. Focuses on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation. It treats cancer and inflammatory conditions by targeting the metabolism of immune cells. The company was founded by Houman Ashrafian, Paul-Peter Tak, Luke O'Neill, Jonathan Powell, Jeff Rathmell and Michael Rosenblum and is headquartered in London, the United Kingdom. | Health Technology |
Ervaxx Ltd.
Ervaxx Ltd. Pharmaceuticals: MajorHealth Technology Ervaxx Ltd. is a British company that pioneers the use of dark antigens to deliver targeted immunotherapies for treating and preventing cancer. The company was founded in 2016 by George Kassiotis, Drew M. Pardoll and is based in London, UK. The company's powerful, proprietary edapt platform has been developed to discover and validate dark antigens providing an in-depth assessment of candidate antigens on primary tumor cells along with their immunogenic potential. Ervaxx is advancing a pipeline of T cell receptor-based therapies, off-the-shelf cancer vaccines, and other immunotherapies leveraging these insights into the role of dark antigens in cancer. | Health Technology |
Therini Bio, Inc.
 Therini Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Therini Bio, Inc. engages in research and development in the field of biotechnology. The company was founded by Katerina Akassoglou in 2016 and is headquartered in San Francisco, CA. | Commercial Services |
Alchemab Therapeutics Ltd.
 Alchemab Therapeutics Ltd. BiotechnologyHealth Technology Alchemab Therapeutics Ltd. engages in developing of antibodies. It focuses on discovering and developing novel therapeutics for patients. The company was founded in 2019 and is headquartered in Kings Cross, the Unite Kingdom. | Health Technology |
Zarodex Therapeutics Ltd.
Zarodex Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Zarodex Therapeutics Ltd. engages in the research and experimental development on biotechnology. The company was founded on July 26, 2017 and is headquartered in London, the United Kingdom. | Commercial Services |
Mestag Therapeutics Ltd.
 Mestag Therapeutics Ltd. Financial ConglomeratesFinance Mestag Therapeutics Ltd. is engaged in the biotechnology industry. The company was founded on February 17, 2020 and is headquartered in Cambridge, the United Kingdom. | Finance |
Cellinta Ltd.
Cellinta Ltd. Investment ManagersFinance Cellinta Ltd. operates as a biotechnology firm. The company was founded on August 16, 2019 and is headquartered in Reading, the United Kingdom. | Finance |
Cybele Therapeutics Ltd.
Cybele Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Cybele Therapeutics Ltd. engages in research and experimental development on biotechnology. The company was founded on August 23, 2019 and is headquartered in Reading, the United Kingdom. | Commercial Services |
Catamaran Bio, Inc.
 Catamaran Bio, Inc. Financial ConglomeratesFinance Catamaran Bio, Inc. provides investment services. The company is headquartered in Delaware. | Finance |
Prilenia Therapeutics BV
 Prilenia Therapeutics BV BiotechnologyHealth Technology Prilenia Therapeutics BV develops and manufactures pharmaceuticals. The company was founded in 2018 and is headquartered in Naarden, the Netherlands. | Health Technology |
TRex Bio Ltd.
 TRex Bio Ltd. BiotechnologyHealth Technology TRex Bio Ltd. is a British company that provides biotechnology research and development services. The private company is based in London, UK. The company was founded in 2018 by Houman Ashrafian. | Health Technology |
| Enara Bio Ltd. | Health Technology |
